Denali Therapeutics (DNLI) Net Cash Flow (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Net Cash Flow data on file, last reported at $182.3 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 256.5% year-over-year to $182.3 million in Q1 2026; TTM through Mar 2026 was $330.7 million, a 15876.67% increase from a year earlier, with the FY2025 full-year figure at $31.9 million, down 33.35% from the prior year.
• Net Cash Flow for Q1 2026 stood at $182.3 million, up from $114.4 million in the prior quarter.
• Over the last five years, Net Cash Flow for DNLI reached as high as $182.3 million in Q1 2026 and fell as low as -$188.5 million in Q1 2022.
• Historically, Net Cash Flow has averaged $5.6 million across 5 years, with a median of $16.0 million in 2024.
• Across the five-year window, Net Cash Flow soared 503.37% in 2024 and slumped 414.87% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $99.4 million in 2022, then sank by 121.03% to -$20.9 million in 2023, then surged by 503.37% to $84.3 million in 2024, then jumped by 35.62% to $114.4 million in 2025, then soared by 59.4% to $182.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $182.3 million in Q1 2026, $114.4 million in Q4 2025, and -$50.2 million in Q3 2025.